Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

IFN treatment during the COVID-19 pandemic

  • Kerry Taylor
  • Kerry Taylor's Avatar Topic Author
4 months 4 days ago #1774 by Kerry Taylor
IFN treatment during the COVID-19 pandemic was created by Kerry Taylor
One of my well-informed CML pts doing well on Imatinib has posed the following question.

They are aware of IFN’s antiviral properties and its activity against coronavirus, and of limited largely anecdotal data on reduced viral infection in CML(including the IRIS study).

Should they change from Glivec to IFN during the pandemic-might this reduce their risk of getting Covid infection?
  • Francois-Xavier Mahon
  • Francois-Xavier Mahon's Avatar Topic Author
4 months 4 days ago - 4 months 4 days ago #1775 by Francois-Xavier Mahon
Replied by Francois-Xavier Mahon on topic IFN treatment during the COVID-19 pandemic
It is an interesting question but in the light of our best understanding my point of view is to avoid to change treatment for the moment. We need to better understand because I am not sure that Interferon alpha would be efficient.

Best wishes
FX
Last edit: 4 months 4 days ago by arlene.
  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar Topic Author
4 months 4 days ago - 4 months 4 days ago #1776 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic IFN treatment during the COVID-19 pandemic
My opinion is to continue the therapy without introducing changes whose efficacy has not been proven, at least for the moment. On the opposite there are suggestions (not yet proven of course) that TKI therapy could be helpful to prevent and/or to be efficacious in the early phases of the Covid infection (see a trial based on this hypothesis approved by EMA just yesterday at the link www.clinicaltrialsregister.eu/ctr-search...al/2020-001236-10/NL So the only advice that in Italy we are giving to our CML patients is to continue the TKI therapy that they are assuming and to try to avoid interpersonal contacts, staying at home and being compliant to all the other restrictions imposed by the health authorities.

Yours, Beppe
Last edit: 4 months 4 days ago by arlene.
  • Jorge Cortes
  • Jorge Cortes's Avatar Topic Author
4 months 4 days ago - 4 months 4 days ago #1777 by Jorge Cortes
Replied by Jorge Cortes on topic IFN treatment during the COVID-19 pandemic
I believe the potential benefit of interferon in this situation is, at best, hypothetical. We have no evidence of any clinical value in preventing or treating this infection. In this context I do not think there would be a good reason to change therapy, even less if treatment with imatinib is going well.
Last edit: 4 months 4 days ago by arlene.
  • Andrija Bogdanovic
  • Andrija Bogdanovic's Avatar Topic Author
4 months 4 days ago - 4 months 4 days ago #1779 by Andrija Bogdanovic
Replied by Andrija Bogdanovic on topic IFN treatment during the COVID-19 pandemic
If patient is doing well, why to change treatment at all ?

Data about current Interferon treatment of viral illness like SARS-Cov2 are rare, and most data about use of IFN originate quite time ago. Chinese did not report frequent number of patients treated with IFN in COVID19 according to published information in peer sources, except different press. On the other side we as hematologist know that even in best scenario IFN is not working well for large bulk of CML patients and in all our guidance is not recommended INF except in trials.
Moreover we have data about effects of imatinib in immune modulation, isn't it (ICMLF correspondence)?

Another information to patients (it is probably important to provide part of this correspondence to CML advocates as well) is that side effects of interferon are sometimes quite similar to CODIV19. Moreover interferon supplies in Europe are cut by stopping of its production by Roche in last year. In Eastern Europe we have not seen IFN for almost a year due to vendors.
Best for all of our patients is keep personal distance, home isolation and regular therapy with current TKI , not to have patients loosing their previous response.
For those who tackle Cov2 infection, we will work with infection medicine specialists to save their life.
Last edit: 4 months 4 days ago by arlene.
Moderators: Melissa Davis-Bishop